

AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below. A complete listing of the claims is set forth below.

1-37 **(Cancelled)**

38. **(New)** A non-naturally occurring composition comprising:

a recombinant Tankyrase H protein; and

a source of ADP ribose;

wherein said composition exhibits poly-ADP ribose polymerase activity.

39. **(New)** The composition of claim 38, further comprising:

a test agent.

40. **(New)** The composition of claim 38, wherein said test agent is an organic molecule of less than 2,500 Da.

41. **(New)** The composition of claim 38, wherein the test agent is a peptide.

42. **(New)** The composition of claim 38, wherein said composition is a cellular composition comprising cells comprising:

a recombinant nucleic acid encoding said Tankyrase H protein.

43. **(New)** The composition of claim 38, wherein said Tankyrase H protein is a fusion protein.

44. **(New)** The composition of claim 38, wherein said cell is a mammalian cell.

45. **(New)** A method of using the composition of claim 38, comprising:
contacting the composition of claim 38 with a test agent; and

determining any effect of said test agent on said poly-ADP ribose polymerase activity.

46. **(New)** The method of claim 45, wherein said test agent is an organic molecule of less than 2,500 Da.

47. **(New)** The method of claim 45, wherein the test agent is a peptide.

Formal matters

Claims 38 to 47 are pending.

Claims 1-37 were cancelled without prejudice.

Claims 38-47 are newly added. Support for new claims 38-47 is found in claims 20-23 as originally filed, as well as page 3, lines 36-36; page 4, lines 26-36; page 8 lines 5-18; page 11, lines 25-page 12 line 10; page 29 lines 3-21; page 35 lines 19-32; page 37, lines 14-29 and page 61 lines 35-40. No new matter is added.

Restriction Requirement

In the Restriction Requirement, the Examiner requires election of one of the following groups of claims:

- Group I: Claim 1; drawn to a screening method;
- Group II: Claims 2-3; drawn to a screening method;
- Group III: Claims 4-5 and 7-8, drawn to a screening method;
- Group IV: Claim 6, drawn to a diagnostic method;
- Group V: Claim 9; drawn to a method of treatment;
- Group VI: Claims 10-19; drawn to a polynucleotide;
- Group VII: Claims 20-23; drawn to a polypeptide;
- Group VIII: Claims 24-26; drawn to an antibody;
- Group IX: Claims 27-30; drawn to a screening method;
- Group X: Claims 31-34; drawn to a screening method; and
- Group XI: Claims 35-37; drawn to a method of inhibiting growth of a cell.

The Applicants hereby elect to prosecute the claims of **Group VII**, claims 20-23, with traverse.

New claims 38-44 are drawn to similar subject matter as the elected group. New claims 44-47 represent a method of using the subject matter of claims 38 and therefore should not be restricted from claims 44-47.

Entry and examination of new claims 38 to 47 is respectfully requested.


As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine the entire application on the merits, even though the entire application includes claims to independent or distinct inventions. It is the Applicants' position that it would not be unduly burdensome to perform a search on all of the claims together in the present application. Accordingly, the Applicants traverse the restriction requirement.

The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number RIGL-010CIP3.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 17, 2006

By: 
James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\RIGL (Rigel)\010CIP3\Response to Restriction Requirement dated January 19, 2006.doc